Pharma video ads surge after initial COVID-19 slowdown, adtech company tracks significant year-over-year growth

voice recognition for mobile phones
Pharma video ads flourished on mobile phones lately, but also expanded on connected TV during the pandemic, says one ad tracker. (Pixabay)

After a short pause in March, pharma video ads have bounced back. Initial COVID-19 shelter-in-place advice and uncertainty dampened pharma video placement. However, video ad tech company Innovid has since tracked consistent growth.

Pharma video volume, in fact, led all categories with 85% year-over-year growth for the last week of July. The pharma market saw jumps in both broadcast (10%) and programmatic (9%) video ads for the week.

RELATED: Pharma and healthcare boost digital ad spend on the way to $4.5B in 2021

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

“In pharma, we saw a small dip at the beginning, but there has been a nice comeback then through the entire time,” Innovid co-founder and CTO Tal Chalozin, said.

While maybe obvious, pharma products tend to be more recession proof during economic downturns in general, along with a few other categories such as consumer packaged goods (CPG).In fact, pharma, CPG and telecom were the three biggest ad categories seeing year-over-year growth in video ad impressions through the end of July, according to Innovid.

Led by pharma, the uptick in programmatic video ads repeated across multiple categories. The moves were driven by the need for flexibility and convenience during the pandemic, Chalozin said. Programmatic ads, which are automatically placed basde on advertisers’ pre-selected metrics such as audience and budget details, found fans with industries’ looking to be more agile during the crisis.

RELATED: Pharma's digital ad spending set for a leap in 2020 as TV flattens out, forecast says

In conversations with marketers across verticals, many said they shifted to programmatic to be able to move more quickly to find audiences or to reconfigure ad budgets on the fly. That second reason—the ability to quickly shift ad spending during the COVID-19 crisis—was especially true. Chalozin pointed to the example of sporting and live events getting cancelled or postponed and advertisers stuck with pre-paid media spent on broadcast TV.

When it came to where viewers were watching video ads, mobile was the no-surprise winner at 47% at the end of July. However, connected TV wasn’t far behind at 37%, and a jump over last year’s more typical highs in the upper 20 percentiles.

Chalozin said he expects connected TV, like programmatic, is another COVID-19 trend that will continue to hold going forward in video advertising.

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.